Lung Cancer: NSCLC and SCLC — Screening, Staging, and Targeted Therapy

Lung cancer represents the leading cause of cancer-related mortality worldwide, accounting for approximately 1.8 million deaths annually. [KEY_CONCEPT] The disease is broadly classified into two major histologic types: non-small cell lung cancer (NSCLC), comprising 85% of cases, and small cell lung cancer (SCLC), representing 15% of cases.

NSCLC Subtypes:

• Adenocarcinoma (40-45%): Most common subtype, often peripheral, associated with non-smokers
• Squamous cell carcinoma (25-30%): Typically central, strongly associated with smoking
• Large cell carcinoma (5-10%): Poorly differentiated, heterogeneous group

Risk Factors:

• Tobacco smoking (85-90% of cases) [3]
• Environmental tobacco smoke (10-15% increased risk)
• Occupational exposures: asbestos, radon, diesel exhaust
• Family history and genetic predisposition
• Air pollution and ionizing radiation

[CLINICAL_PEARL] While smoking remains the predominant risk factor, the increasing incidence of lung adenocarcinoma in never-smokers, particularly young Asian women, highlights the importance of genetic and environmental factors beyond tobacco exposure.

Epidemiologic Trends:

• Declining incidence in men, stable/increasing in women
• Shifting histology from squamous to adenocarcinoma
• Earlier detection through screening programs
• Improved survival with targeted therapies and immunotherapy

[HIGH_YIELD] The clinical presentation of lung cancer varies significantly based on tumor location, stage, and histologic type. Unfortunately, most patients present with advanced disease due to the asymptomatic nature of early-stage lung cancer.

Primary Tumor Symptoms:

• Persistent cough (most common, 65-75% of patients)
• Dyspnea (55-60% of patients)
• Chest pain (45-50% of patients)
• Hemoptysis (25-35% of patients)
• Hoarseness (vocal cord paralysis from recurrent laryngeal nerve involvement)

Systemic Symptoms:

• Constitutional symptoms: weight loss, fatigue, anorexia
• Bone pain (skeletal metastases)
• Neurologic symptoms (brain metastases)
• Abdominal pain (liver metastases)

Paraneoplastic Syndromes:

[CLINICAL_PEARL] Superior vena cava syndrome presents with facial swelling, neck vein distension, and upper extremity edema, requiring urgent evaluation and treatment.

Physical Examination Findings:

• Respiratory: decreased breath sounds, pleural effusion, stridor
• Cardiovascular: elevated JVP (SVC syndrome), pericardial effusion
• Neurologic: focal deficits (brain metastases), muscle weakness
• Musculoskeletal: digital clubbing, bone tenderness

[KEY_CONCEPT] Lung cancer screening with low-dose computed tomography (LDCT) has revolutionized early detection, demonstrating a 20% reduction in lung cancer mortality in high-risk populations [3].

Current Screening Guidelines (USPSTF 2021):

LDCT Screening Criteria: ├─ Age 50-80 years ├─ ≥20 pack-year smoking history ├─ Current smoker OR quit within 15 years ├─ Life expectancy ≥10 years └─ No symptoms suggestive of lung cancer

[HIGH_YIELD] Lung-RADS Classification System:

• Category 1: No nodules or benign-appearing nodules
• Category 2: Benign-appearing nodules, routine screening
• Category 3: Probably benign, 6-month follow-up
• Category 4A: Suspicious, 3-month follow-up or PET/CT
• Category 4B: Very suspicious, 1-month follow-up or tissue sampling
• Category 4X: Additional findings warranting evaluation

Diagnostic Workup Algorithm:

Suspicious Pulmonary Nodule ├─ CT chest with contrast ├─ PET/CT (if nodule >8mm or suspicious features) ├─ Tissue Acquisition: │ ├─ Bronchoscopy (central lesions) │ ├─ Transthoracic needle biopsy (peripheral lesions) │ ├─ Mediastinoscopy/EBUS (mediastinal lymph nodes) │ └─ Thoracotomy (if other methods non-diagnostic) └─ Molecular Testing (if malignant): ├─ EGFR mutations ├─ ALK rearrangements ├─ ROS1 rearrangements ├─ BRAF mutations ├─ PD-L1 expression └─ Comprehensive genomic profiling

Essential Molecular Testing for NSCLC:

• EGFR mutations (15-20% of adenocarcinomas)
• ALK rearrangements (3-5% of adenocarcinomas)
• ROS1 rearrangements (1-2% of NSCLCs)
• BRAF mutations (1-3% of adenocarcinomas)
• PD-L1 expression (immunotherapy biomarker)
• Microsatellite instability (MSI-H) (rare but targetable)

[CLINICAL_PEARL] Liquid biopsy using circulating tumor DNA (ctDNA) is increasingly utilized for molecular profiling when tissue is insufficient or inaccessible, though tissue-based testing remains the gold standard.

[KEY_CONCEPT] Accurate staging is crucial for treatment planning and prognosis determination. The TNM staging system (8th edition) is used for NSCLC, while SCLC uses a simplified limited vs. extensive disease classification.

NSCLC Staging (TNM 8th Edition):

SCLC Staging:

• Limited Disease: Confined to one hemithorax, including ipsilateral mediastinal and supraclavicular lymph nodes
• Extensive Disease: Disease beyond limited disease boundaries

Staging Workup:

Staging Evaluation ├─ History & Physical Examination ├─ Performance Status Assessment (ECOG/Karnofsky) ├─ Laboratory Studies: │ ├─ CBC with differential │ ├─ Comprehensive metabolic panel │ ├─ Liver function tests │ └─ Lactate dehydrogenase ├─ Imaging: │ ├─ CT chest/abdomen/pelvis with contrast │ ├─ Brain MRI (stages II-IV or symptomatic) │ ├─ PET/CT (potentially resectable disease) │ └─ Bone scan (if PET unavailable) └─ Pulmonary Function Tests (if surgery considered)

[HIGH_YIELD] Key T-Descriptors (8th Edition Changes):

• T1: ≤3 cm (subdivided: T1a ≤1 cm, T1b >1-2 cm, T1c >2-3 cm)
• T2: >3-5 cm (T2a >3-4 cm, T2b >4-5 cm)
• T3: >5-7 cm or separate nodules in same lobe
• T4: >7 cm or separate nodules in different ipsilateral lobe

[CLINICAL_PEARL] Oligometastatic disease (1-5 metastatic lesions) is increasingly recognized as a distinct clinical entity with potential for aggressive local therapy and improved outcomes.

[KEY_CONCEPT] Lung cancer treatment has been revolutionized by precision medicine, with targeted therapies and immunotherapy significantly improving outcomes for patients with specific molecular alterations.

NSCLC Treatment by Stage:

Early-Stage NSCLC (Stages I-II):

Surgical Candidates ├─ Lobectomy (preferred) or Sublobar resection ├─ Mediastinal lymph node sampling/dissection └─ Adjuvant chemotherapy (stage IB-II, tumor ≥4 cm)

Non-Surgical Candidates ├─ Stereotactic body radiation therapy (SBRT) │ ├─ 3-5 fractions, high-dose/fraction │ └─ 90% local control at 3 years └─ Conventional radiation therapy (poor SBRT candidates)

Advanced NSCLC Treatment Algorithm:

Metastatic NSCLC ├─ Molecular Testing Results: │ ├─ EGFR Mutation (+) │ │ ├─ First-line: Osimertinib │ │ └─ Alternative: Erlotinib, Gefitinib, Afatinib │ ├─ ALK Rearrangement (+) │ │ ├─ First-line: Alectinib or Lorlatinib │ │ └─ Alternative: Crizotinib, Ceritinib │ ├─ ROS1 Rearrangement (+) │ │ └─ First-line: Crizotinib or Entrectinib │ ├─ BRAF V600E Mutation (+) │ │ └─ Dabrafenib + Trametinib │ └─ No Targetable Mutation: │ ├─ PD-L1 ≥50%: Pembrolizumab monotherapy │ ├─ PD-L1 1-49%: Chemotherapy + Immunotherapy │ └─ PD-L1 <1%: Chemotherapy ± Immunotherapy

[HIGH_YIELD] Key Targeted Therapies:

SCLC Treatment:

Limited Disease SCLC ├─ Concurrent chemoradiation │ ├─ Platinum + Etoposide │ └─ Thoracic radiation (45 Gy) ├─ Prophylactic cranial irradiation (if CR/PR) └─ Consider surgical resection (T1-2, N0)

Extensive Disease SCLC ├─ First-line: Platinum + Etoposide + Atezolizumab ├─ Maintenance: Atezolizumab ├─ Second-line: │ ├─ Topotecan (sensitive relapse) │ ├─ Lurbinectedin (refractory disease) │ └─ Nivolumab (after progression)

[CLINICAL_PEARL] Resistance mechanisms to targeted therapies are common and include secondary mutations (e.g., T790M in EGFR), bypass pathways, and histologic transformation. Sequential molecular testing at progression is essential.

Immunotherapy Combinations:

• Keynote-189: Pembrolizumab + carboplatin + pemetrexed (non-squamous)
• Keynote-407: Pembrolizumab + carboplatin + paclitaxel/nab-paclitaxel (squamous)
• CheckMate-9LA: Nivolumab + ipilimumab + 2 cycles chemotherapy

[KEY_CONCEPT] Lung cancer complications arise from local tumor effects, metastatic disease, treatment-related toxicities, and paraneoplastic syndromes. Early recognition and management are crucial for maintaining quality of life and treatment compliance.

Oncologic Emergencies:

Superior Vena Cava Syndrome:

• Presentation: Facial swelling, neck vein distension, dyspnea, chest discomfort
• Management: High-dose corticosteroids, urgent radiation therapy or chemotherapy
• Prognosis: Symptom relief in 70-90% within 2 weeks

Malignant Pleural Effusion:

• Incidence: 15% of lung cancer patients
• Management: Thoracentesis → pleurodesis (talc preferred)
• Prognosis: Median survival 3-12 months

Spinal Cord Compression:

• Presentation: Back pain, neurologic deficits, bladder/bowel dysfunction
• Management: High-dose corticosteroids, urgent radiation therapy
• Timing: Treatment within 24-48 hours optimal

Treatment-Related Toxicities:

Targeted Therapy Side Effects:

[HIGH_YIELD] Immune-Related Adverse Events (irAEs):

• Pneumonitis: Most concerning, can be fatal
• Hepatitis: Monitor liver enzymes regularly
• Colitis: Diarrhea, abdominal pain
• Endocrinopathies: Thyroid dysfunction, adrenal insufficiency

Management of irAEs:

Grade 1 (Mild) ├─ Continue immunotherapy ├─ Monitor closely └─ Symptomatic management

Grade 2 (Moderate) ├─ Hold immunotherapy ├─ Corticosteroids (0.5-1 mg/kg/day prednisone) └─ Resume when grade ≤1

Grade 3-4 (Severe/Life-threatening) ├─ Permanently discontinue immunotherapy ├─ High-dose corticosteroids (1-2 mg/kg/day) ├─ Consider additional immunosuppression └─ Specialist consultation

Long-term Surveillance:

Post-treatment Follow-up Schedule:

• Years 1-2: Every 3-4 months with CT chest
• Years 3-5: Every 6 months with CT chest
• After 5 years: Annual history, physical exam, and imaging

[CLINICAL_PEARL] Smoking cessation remains the most important intervention for lung cancer patients, reducing second primary cancers by 30-50% and improving treatment outcomes.

Quality of Life Considerations:

• Palliative care: Early integration improves survival and quality of life
• Nutritional support: Cachexia affects 50-80% of advanced patients
• Psychosocial support: Depression and anxiety are common
• Symptom management: Dyspnea, pain, fatigue require proactive management

Prognosis Factors:

• Performance status: Most important prognostic factor
• Stage at diagnosis: 5-year survival varies from 92% (IA1) to 0% (IVB)
• Molecular alterations: EGFR/ALK patients have better outcomes
• Response to therapy: Complete response associated with improved survival